Anemia, a common hematological disorder, presents a diagnostic challenge due to its multifactorial etiology. This guide aims to simplify the approach to diagnosing anemia, essential for delivering optimal patient care.
The first step in diagnosing anemia involves a thorough patient history and physical examination. Clinical features such as fatigue, pallor, and dyspnea on exertion can indicate anemia, but these are non-specific and can vary based on the severity and acuity of the anemia. Laboratory tests including complete blood count (CBC) and reticulocyte count are indispensable in the initial evaluation.
Classifying anemia based on the mean corpuscular volume (MCV) can provide valuable clues to its cause. Microcytic anemia (MCV<80 fL) is often due to iron deficiency or thalassemia. Normocytic anemia (MCV 80-100 fL) can be due to chronic disease, acute blood loss, or bone marrow dysfunction. Macrocytic anemia (MCV>100 fL) may be due to vitamin B12 or folate deficiency, myelodysplastic syndrome, or medication side effects.
Further diagnostic testing is guided by the MCV and clinical suspicion. Iron studies, hemoglobin electrophoresis, vitamin B12 and folate levels, and bone marrow biopsy may be required. Evaluation of the peripheral smear can provide additional diagnostic clues.
Management of anemia is dependent on the underlying cause. Iron supplementation is the mainstay for iron deficiency anemia, while B12 or folate supplementation is used for macrocytic anemias. Referral to a hematologist may be warranted for complex cases or when the diagnosis is uncertain.
Diagnosing anemia requires a systematic approach, beginning with a thorough history and physical examination, followed by laboratory testing and classification based on MCV. Further diagnostic testing is guided by these results and clinical suspicion. Understanding this approach is crucial for healthcare professionals in delivering optimal patient care.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation